Oncology: from the daily briefing

Every daily briefing item tagged oncology, newest first. The weekly roundup is on the oncology page.

• Oct 27, 2026Laparoscopic and open resection of colorectal liver metastases compared in individual participant data meta-analysisEvidence
• Oct 26, 2026Coherence Neuro raises $45 million for investigational implants that read tumor-linked brain signalsShareMoney
• Oct 26, 2026Sacituzumab tirumotecan compared with physician's choice in previously treated endometrial cancer in phase 3 TroFuse-005Evidence
• Oct 26, 2026First-line pembrolizumab compared with carboplatin-paclitaxel in mismatch repair-deficient endometrial cancerEvidence
• Oct 26, 2026Children's Oncology Group issues guideline on cancer genetics evaluation for childhood cancer survivorsEvidence
• Oct 26, 2026International consensus guideline on curative-intent care of de novo metastatic nasopharyngeal carcinomaEvidence
• Oct 26, 2026Advanced Prostate Cancer Consensus Conference reports panel views on high-risk and recurrent prostate cancerEvidence
• Oct 26, 2026Tandem CD20-CD19 CAR T-cell therapy tested second line in transplant-ineligible large B-cell lymphomaEvidence
• Oct 26, 2026Izalontamab brengitecan compared with platinum chemotherapy in EGFR-mutated NSCLC after progressionEvidence
• Oct 26, 2026Ruzaltatug rezetecan compared with chemotherapy in EGFR-mutated NSCLC after EGFR inhibitor therapyEvidence
• Oct 26, 2026Izalontamab brengitecan compared with chemotherapy in pretreated HR-positive, HER2-negative breast cancerEvidence
• Oct 26, 2026Dalmelitinib plus aumolertinib lengthens progression-free survival in EGFR-TKI-resistant NSCLC with MET amplificationEvidence
• Oct 26, 2026BioNTech reports modest efficacy and lung toxicity in phase 3 trial of HER2-directed antibody-drug conjugateEvidence
• Oct 25, 2026Siemens Healthineers and Nvidia plan AI agents and patient digital twins for radiotherapy planningShareMoney
• Oct 25, 2026Sacituzumab tirumotecan plus pembrolizumab lengthens progression-free survival in PD-L1-negative advanced NSCLCEvidence
• Oct 25, 2026Personalized mRNA vaccine intismeran plus pembrolizumab improves recurrence-free survival in resected melanomaEvidence
• Oct 25, 2026Divarasib lengthens progression-free survival over sotorasib or adagrasib in KRAS G12C-mutated NSCLCEvidence
• Oct 25, 2026Osimertinib plus savolitinib lengthens progression-free survival in EGFR-mutated NSCLC with MET overexpressionEvidence
• Oct 24, 2026Tarlatamab plus durvalumab maintenance improves survival in extensive-stage small cell lung cancer in phase 3 trialEvidence
• Oct 24, 2026Durvalumab with neoadjuvant enfortumab vedotin improves event-free survival in cisplatin-ineligible bladder cancerEvidence
• Oct 24, 2026Anbenitamab plus HB1801 improves 24-month progression-free survival in HER2-positive advanced breast cancerEvidence
• Oct 22, 2026Nebraska Medicine shelves its in-house AI cancer registry tool after it reaches a little over 80% accuracy against a 95% barShareDeployment
• Oct 21, 2026AI model trained on 40 million face photos sorts cancer patients by survival risk, Lancet Digital Health study findsShareEvidence
• Oct 21, 2026Home and virtual supportive oncology program tied to 10.4% fewer admissions among 5,432 Rhode Island cancer patientsShareEvidence
• Oct 18, 2026FDA clears SimBioSys software that estimates breast cancer recurrence risk from MRI, pathology and clinical dataShareRegulation
• Oct 11, 2026Mayo Clinic system grades radiation side effects from recorded visits with 82.6% exact agreement, near the range of expert ratersShareEvidence
• Oct 9, 2026Review finds only one of 18 radiation oncology AI deployments in lower-income countries reached cross-stage workflow useShareEvidence